PCSK9 and hypertensive disorder: In summary, in the treatment of high-risk CVD patients, the combination of astatin and a PCSK9 inhibitor was safe and more effective in lowering lipid levelsand achieving the target than other rosuvastatin-based regimens, while theaddition of ezetimibe was unable to significantly lower lipid levels any further.The rate of achieving the target was higher in patients with hypertension and lowBMI.